title: [Use of magnesium sulfate in hypertrophic cardiomyopathy with stenosis of the outflow route].
abstract: 10 patients with hypertrophic cardiomyopathy with left ventricular outflow obstruction were intravenously given 100 mg/kg b.w. of magnesium sulphate. Significant decrease of repolarization disorders was observed in ecg recordings. Polycardiographically estimated prolonged A2-O interval significantly shortened from 188 +/- 49 to 168 +/- 45 ms. Echocardiographic examinations revealed increase of the left ventricular end-diastolic dimension from 43 +/- 6 to 45 +/- 6 mm (p less than 0.05), acceleration of the diastolic, posterior wall motion from 5.7 +/- 3 cm/s to 7.2 +/- 2 cm/s (p less than 0.01) and shortening of prolonged left ventricular isovolumetric relaxation interval from 108 +/- 15 to 94 +/- 14 ms (p less than 0.05). Intrasystolic anterior, mitral leaflet motion towards the intraventricular septum also significantly decreased. There were no changes of heart rate, blood pressure and left ventricular systolic parameters after MgSO4 administration. Obtained data indicate the dynamic nature of left ventricular diastolic function impairment and its positive modification by magnesium sulphate administration.
authors.forename: A
authors.initials: A
authors.lastname: Szyszka
authors.forename: A
authors.initials: A
authors.lastname: Pieczyńska
mesh_terms: D000328:Adult; D002312:Cardiomyopathy, Hypertrophic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006352:Heart Ventricles / Q000187:drug effects / Q000503:physiopathology; D006801:Humans; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000187:drug effects / Q000503:physiopathology; D008946:Mitral Valve Stenosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D008278:Magnesium Sulfate
vernacular_title: Zastosowanie siarczanu magnezu w kardiomiopatii przerostowej ze zwezeniem drogi odpływu.